Sunday Surprises

On this last day of January, I have a bowl full of Katfood to spoil you with...   All this Katfood just for me - yummy! Blocking injunct...
- Sunday, January 31, 2021
Sunday Surprises Sunday Surprises Reviewed by Magdaleen Jooste on Sunday, January 31, 2021 Rating: 5
Never Too Late: if you missed The IPKat last week Never Too Late: if you missed The IPKat last week Reviewed by Anastasiia Kyrylenko on Sunday, January 31, 2021 Rating: 5
[Guest Post] The Nigerian Companies And Allied Matters Act 2020 and the protection of trademarks against similar company names [Guest Post] The Nigerian Companies And Allied Matters Act 2020 and the protection of trademarks against similar company names Reviewed by Chijioke Okorie on Thursday, January 28, 2021 Rating: 5
The 'goldfish phone booth' copyright case in Japan The 'goldfish phone booth' copyright case in Japan Reviewed by Tian Lu on Wednesday, January 27, 2021 Rating: 5

Around the IP Blogs

This Kat has had a revelation   This Kat can hardly believe that it's already the last week of an eventful January. What better way to u...
- Wednesday, January 27, 2021
Around the IP Blogs Around the IP Blogs Reviewed by Sophie Corke on Wednesday, January 27, 2021 Rating: 5
Impact of the proposed EU Regulation on Markets in Crypto-assets for IP applications Impact of the proposed EU Regulation on Markets in Crypto-assets for IP applications Reviewed by Neil Wilkof on Tuesday, January 26, 2021 Rating: 5
General Court affirms minimal distinctiveness requirement in Oatly's trade mark appeal General Court affirms minimal distinctiveness requirement in Oatly's trade mark appeal Reviewed by Sophie Corke on Monday, January 25, 2021 Rating: 5
Will the last entrepreneurial person leaving the Bay Area please turn off the lights? Will the last entrepreneurial person leaving the Bay Area please turn off the lights? Reviewed by Neil Wilkof on Monday, January 25, 2021 Rating: 5
Canadian Federal Court considers whether Teva's COPAXONE second medical use patents were obvious-to-try (Teva v Pharmascience) Canadian Federal Court considers whether Teva's COPAXONE second medical use patents were obvious-to-try (Teva v Pharmascience) Reviewed by Rose Hughes on Monday, January 25, 2021 Rating: 5
Book review: Drafting Copyright Exceptions Book review: Drafting Copyright Exceptions Reviewed by Hayleigh Bosher on Sunday, January 24, 2021 Rating: 5
Never Too Late: if you missed The IPKat last week Never Too Late: if you missed The IPKat last week Reviewed by Magdaleen Jooste on Sunday, January 24, 2021 Rating: 5
Powered by Blogger.